NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma

被引：0

作者：

Dean, Andrew ^{[1
]}

Wainberg, Zev A. ^{[2
]}

Bekaii-Saab, Tanios S. ^{[3
]}

Hubner, Richard ^{[4
]}

Macarulla, Teresa ^{[5
]}

Paulson, Andrew Scott ^{[6
]}

Cutsem, Eric V. ^{[7
]}

Maxwell, Fiona ^{[8
]}

Moore, Yan ^{[9
]}

Wang, Haofei Tiffany ^{[9
]}

Zhang, Bin ^{[9
]}

O'Reilly, Eileen ^{[10
]}

机构：

[1] St John God Subiaco, Subiaco, WA, Australia

[2] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA

[3] Mayo Clin Canc Ctr MCCC, Scottsdale, AZ USA

[4] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[5] Vall Hebron Univ Hosp, Barcelona, Spain

[6] US Oncol Network, Texas Oncol, Dallas, TX USA

[7] Univ Leuven, Leuven, Belgium

[8] Ipsen, Abingdon, Oxon, England

[9] Ipsen Biosci Inc, Cambridge, MA USA

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

407

引用

页码：202 / 203

页数：2